Coronavirus
Brands must take extra caution against counterfeits during Covid-19 pandemic
By Mette Parlev | Posted on June 5, 2020
Enhanced online brand protection and anti-counterfeiting measures are needed due to the current pandemic: as demand from e-commerce consumers increases, so does the market for counterfeits. Background A recent report from EUROPOL, the European Union’s law enforcement agency, provides an overview of how criminals are adapting to profit from the covid-19 pandemic. Findings include that...
Tags: anti-counterfeiting, Coronavirus, COVID-19, enforcement, EU, Europe, trademarks
What patent protection does Gilead’s COVID-19 treatment Remdesivir have?
By Anders Heebøll-Nielsen, Michael Bech Sommer | Posted on April 30, 2020
On 29 April 2020 Gilead announced that its drug Remdesivir has a positive effect in the treatment of COVID-19 from a phase three trial of the drug. The investigation was so successful that for ethical reasons it was “unblinded” – the effect observed was so significant that retaining the group on placebo would prevent those...
Tags: applications, Coronavirus, COVID-19, Gilead, IPR protection, patents, PCT, Remdesivir
Recent contributors
Partner, European Patent Attorney
Senior Associate, Attorney at Law
Partner, Attorney at Law, Group Vice President
Partner, Attorney at Law, Business Area Manager
Senior Counsel, European Patent Attorney
